Clinical trials in the era of personalized oncology

Ca-A Cancer Journal for Clinicians

61, 365-381

DOI: 10.3322/caac.20135

Citation Report

#	Article	IF	Citations
1	Trastuzumab and Congestive Heart Failure: What Can We Learn From Use in the Community?. Journal of the National Cancer Institute, 2012, 104, 1269-70.	6.3	2
2	The importance of primary care research in the management of respiratory disease. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2012, 21, 1-3.	2.3	4
3	Epigenetics advancing personalized nanomedicine in cancer therapy. Advanced Drug Delivery Reviews, 2012, 64, 1532-1543.	13.7	35
4	â€˜Personalized Medicineâ€™ To Identify Genetic Risks For Type 2 Diabetes And Focus Prevention: Can It Fulfill Its Promise?. Health Affairs, 2012, 31, 43-49.	5.2	18
5	BEAMing Up Personalized Medicine: Mutation Detection in Blood. Clinical Cancer Research, 2012, 18, 3209-3211.	7.0	42
6	RECIST: No Longer the Sharpest Tool in the Oncology Clinical Trials Toolboxâ€”Point. Cancer Research, 2012, 72, 5145-5149.	0.9	77
7	Reliable Biomarkers and Predictors of Schizophrenia and its Treatment. Psychiatric Clinics of North America, 2012, 35, 645-659.	1.3	29
8	Modeling NSCLC Progression: Recent Advances and Opportunities Available. AAPS Journal, 2013, 15, 542-550.	4.4	12
9	Predicting outcomes in radiation oncologyâ€”multifactorial decision support systems. Nature Reviews Clinical Oncology, 2013, 10, 27-40.	27.6	329
10	Companion Biomarkers: Paving the Pathway to Personalized Treatment for Cancer. Clinical Chemistry, 2013, 59, 1447-1456.	3.2	44
11	Biological Therapies for Cancer. , 2013, , 303-342.		2
12	Estimation of Renal Cell Carcinoma Treatment Effects From Disease Progression Modeling. Clinical Pharmacology and Therapeutics, 2013, 93, 345-351.	4.7	11
13	In situ Protein Detection for Companion Diagnostics. Frontiers in Oncology, 2013, 3, 271.	2.8	9
14	Individualizing breast cancer treatmentâ€”The dawn of personalized medicine. Experimental Cell Research, 2014, 320, 1-11.	2.6	26
15	Five-year experience with setup and implementation of an integrated database system for clinical documentation and research. Computer Methods and Programs in Biomedicine, 2014, 114, 206-217.	4.7	39
16	Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncology, The, 2014, 15, e8-e21.	10.7	413
17	NOD-scidIl2rg tm1Wjl and NOD-Rag1 null Il2rg tm1Wjl : A Model for Stromal Cellâ€“Tumor Cell Interaction for Human Colon Cancer. Digestive Diseases and Sciences, 2014, 59, 1169-1179.	2.3	52
18	Why the Shift? Taking a Closer Look at the Growing Interest in Niche Markets and Personalized Medicine. World Medical and Health Policy, 2015, 7, 3-27.	1.6	8

#	Article	IF	Citations
19	Data management, documentation and analysis systems in radiation oncology: a multi-institutional survey. Radiation Oncology, 2015, 10, 230.	2.7	8
20	Molecular Imaging to Identify Tumor Recurrence following Chemoradiation in a Hostile Surgical Environment. Molecular Imaging, 2015, 14, 7290.2014.00051.	1.4	3
21	PLGA-Loaded Gold-Nanoparticles Precipitated with Quercetin Downregulate HDAC-Akt Activities Controlling Proliferation and Activate p53-ROS Crosstalk to Induce Apoptosis in Hepatocarcinoma Cells. Molecules and Cells, 2015, 38, 518-527.	2.6	89
22	Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 689-721.	5.2	93
23	Review of Developments in Electronic, Clinical Data Collection, and Documentation Systems over the Last Decade â€“ Are We Ready for Big Data in Routine Health Care?. Frontiers in Oncology, 2016, 6, 75.	2.8	14
24	The Role of Gastrin and CCK Receptors in Pancreatic Cancer and other Malignancies. International Journal of Biological Sciences, 2016, 12, 283-291.	6.4	53
25	Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling. Clinical and Translational Science, 2016, 9, 43-50.	3.1	10
26	The effect of quercetin nanoparticle on cervical cancer progression by inducing apoptosis, autophagy and anti-proliferation via JAK2 suppression. Biomedicine and Pharmacotherapy, 2016, 82, 595-605.	5.6	98
27	Clinical trial designs incorporating predictive biomarkers. Cancer Treatment Reviews, 2016, 43, 74-82.	7.7	61
28	Decision support systems for personalized and participative radiation oncology. Advanced Drug Delivery Reviews, 2017, 109, 131-153.	13.7	113
30	Managing Expectations in the Transition to Proof of Concept Studies. Reviews on Recent Clinical Trials, 2017, 12, 111-123.	0.8	1
32	Cholecystokinin Receptor-Targeted Polyplex Nanoparticle Inhibits Growth and Metastasis of Pancreatic Cancer. Cellular and Molecular Gastroenterology and Hepatology, 2018, 6, 17-32.	4.5	17
33	Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology. JCO Clinical Cancer Informatics, 2018, 2, 1-12.	2.1	14
35	Recent advances in "smart" delivery systems for extended drug release in cancer therapy. International Journal of Nanomedicine, 2018, Volume 13, 4727-4745.	6.7	179
36	Drug cost avoidance in clinical trials of breast cancer. Journal of Oncology Pharmacy Practice, 2019, 25, 1099-1104.	0.9	11
37	Clinical potential of mass spectrometry-based proteogenomics. Nature Reviews Clinical Oncology, 2019, 16, 256-268.	27.6	149
38	Shifting, overlapping and expanding use of â€œprecision oncologyâ€•terminology: a retrospective literature analysis. BMJ Open, 2020, 10, e036357.	1.9	8
39	Bayesian Incentive-Compatible Bandit Exploration. Operations Research, 2020, 68, 1132-1161.	1.9	11

#	Article	IF	Citations
40	The Effect of Quercetin Nanosuspension on Prostate Cancer Cell Line LNCaP via Hedgehog Signaling Pathway. Reports of Biochemistry and Molecular Biology, 2021, 10, 69-75.	1.4	7
41	Quantitative Mass Spectrometry-Based Proteomics for Biomarker Development in Ovarian Cancer. Molecules, 2021, 26, 2674.	3.8	15
42	Integrated analysis identifies a novel lncRNA prognostic signature associated with aerobic glycolysis and hub pathways in breast cancer. Cancer Medicine, 2021, 10, 7877-7892.	2.8	6
43	Increased Jab1/COPS5 is associated with therapeutic response and adverse outcome in lung cancer and breast cancer patients. Oncotarget, 2017, 8, 97504-97515.	1.8	5
44	Concordance of folate receptor-Î± expression between biopsy, primary tumor and metastasis in breast cancer and lung cancer patients. Oncotarget, 2016, 7, 17442-17454.	1.8	63
45	The Effect of Antineoplastons A10 and AS2-1 and Metabolites of Sodium Phenylbutyrate on Gene Expression in Glioblastoma Multiforme. Journal of Cancer Therapy, 2014, 05, 929-945.	0.4	14
46	Purposive-Rational Tumor Therapy: Exploiting the Tumorâ€™s â€˜Living Worldâ€™ for Diversifying, Specifying and Personalizing Tumor Therapy. , 2013, , 261-288.		0
47	Genomic Expression Profiles: From Molecular Signatures to Clinical Oncology Translation. , 0, , .		0
48	High Efficacy in Hyperthermia-associated with Polyphosphate Magnetic Nanoparticles for Oral Cancer Treatment. Journal of Nanomedicine & Nanotechnology, 2014, 05, .	1.1	2
49	Translation: Companion Biomarkers: Paving the Pathway to Personalized Treatment for Cancer. Laboratory Medicine Online, 2015, 5, 44.	0.2	0
50	Cancer Diagnosis and Prognosis Assistance Based on MCA. , 2022, , 57-66.		0
51	New challenges in the use of nanomedicine in cancer therapy. Bioengineered, 2022, 13, 759-773.	3.2	40
52	The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update. Frontiers in Immunology, 0, 14, .	4.8	12
53	Multi-omics analysis based on proteomics is fun! : development of proteogenomic software generating sample-specific proteome database and comprehensive kinase activity analysis. Denki Eido, 2023, 67, 5-11.	0.0	0
54	Identification of potential inhibitor(s) against phospholipase A2 using a network pharmacology-based approach. , 2023, , 15-38.		0
55	Concluding Remarks on Target Nanomedicine: Present and Future Aspects. , 2023, , 343-361.		0
56	Application of Nanoparticles in Cancer Treatment: A Concise Review. Nanomaterials, 2023, 13, 2887.	4.1	1